1
|
Marziali M, Pugliese P, Losardo AA, Ribersani M, Anastasi E, Angeloni A, Pavan A, Gentile G. Efficacy and safety of BNT162b2 mRNA vaccine in a cohort of 90 transfusion dependent thalassemia patients. Transfus Med 2024. [PMID: 38632665 DOI: 10.1111/tme.13038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2023] [Revised: 01/29/2024] [Accepted: 03/20/2024] [Indexed: 04/19/2024]
|
2
|
Pasello G, Lorenzi M, Tosi A, Roma A, Pavan A, Scapinello A, Lonardi S, Ferro A, Maso AD, Frega S, Bonanno L, Del Bianco P, Guarneri V, Rosato A. 164P Immune cells distribution and spatial relationship within microenvironment as predictive biomarkers of benefit in extended stage small cell lung cancer patients receiving atezolizumab plus carboplatin and etoposide as first-line treatment. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00418-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
3
|
Lorenzi M, Scattolin D, Del Conte A, Sangiorgi S, Polo V, Pavan A, Pilotto S, Santarpia M, Da Ros V, Maso AD, Ferro A, Frega S, Bortolami A, Bonanno L, Indraccolo S, Guarneri V, Pasello G. EP08.02-104 Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Pretelli G, Pavan A, Dal Maso A, Resi M, Mulargiu C, Ferro A, Benetti B, Lorenzi M, Marinato G, Frega S, Pasello G, Conte P, Guarneri V, Bonanno L. 63P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): Neutrophil to lymphocyte ratio (NLR) and the risk for toxicity recurrence. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Pretelli G, Pavan A, Dal Maso A, Resi M, Mulargiu C, Ferro A, Benetti B, Lorenzi M, Marinato G, Frega S, Pasello G, Conte P, Guarneri V, Bonanno L. 40P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): A real-world analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Bonanno L, Zulato E, Del Bianco P, Nardo G, Attili I, Pavan A, Bragadin AB, Marra L, Calabrese F, Fassan M, Pasello G, Guarneri V, Conte P, Indraccolo S. MA07.01 Dynamic Liquid Biopsy During Immunotherapy Anticipates Hyperprogression And Early Death in Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Fu X, Padmanabhan M, Kumar RG, Basu S, Dorius S, Pavan A. Measuring the impact of influence on individuals: roadmap to quantifying attitude. SOCIAL NETWORK ANALYSIS AND MINING 2021. [DOI: 10.1007/s13278-021-00763-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Bonanno L, Dal Maso A, Pavan A, Zulato E, Esposito G, Fassan M, Nardo G, Pasello G, Guarneri V, Calabrese F, Rea F, Indraccolo S, Conte P. 51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01893-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Bonanno L, Zulato E, Attili I, Nardo G, Pavan A, Paola D, Boscolo Bragadin A, Pasello G, Guarneri V, Conte P, Indraccolo S. 1939P Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
10
|
Bonanno L, Pavan A, Ferro A, Calvetti L, Frega S, Pasello G, Aprile G, Guarneri V, Conte P. Clinical impact of plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz257.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Pavan A, Calvetti L, Dal Maso A, Fabozzi A, Piccin L, Chiarion-Sileni V, Pasello G, Aprile G, Guarneri V, Conte P, Bonanno L. Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Pavan A, Attili I, Pasello G, Guarneri V, Conte PF, Bonanno L. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. J Immunother Cancer 2019; 7:205. [PMID: 31383005 PMCID: PMC6683488 DOI: 10.1186/s40425-019-0690-1] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 07/24/2019] [Indexed: 12/17/2022] Open
Abstract
Management of small cell lung cancer (SCLC) has not changed over the last decades. In more recent years, alterations of DNA repair machinery and other molecular pathways have been identified in SCLC and preclinical data suggest that dysregulation of these pathways might offer new therapeutic opportunities. While immune checkpoint inhibitors (ICIs) have had a major impact on the clinical outcome of several solid tumors, including non-small cell lung cancer, the potential role of ICIs is currently under investigation in SCLC and some promising data are available. However, several clinical and biological hurdles have to be overcome and predictive markers are still eagerly needed. Knowledge of molecular pathways specifically involved in SCLC growth and treatment resistance is essential for a more rational planning of new combinations including ICIs. The present manuscript summarizes the current clinical evidence on immunotherapy in SCLC, describes the molecular bases underlying treatment resistance and discusses the potentialities and the rationale of different therapeutic combinations.
Collapse
|
13
|
Cox C, Castiello L, Mattei M, Santodonato L, D'agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Borgioni S, Carlei D, Monque D, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini S, Rozera C, Arico' E, Capone I, Belardelli F. INTRANODAL TREATMENT WITH IFNΑ-DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.126_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
14
|
Bonanno L, Zulato E, Attili I, Pavan A, Del Bianco P, Nardo G, Boscolo Bragadin A, Pasqualini L, Calabrese F, Fassan M, Pasello G, Guarneri V, Amadori A, Conte P, Indraccolo S. Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz073.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Pavan A, Calvetti L, Dal Maso A, Attili I, Pasello G, Aprile G, Guarneri V, Conte P, Bonanno L. Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Visco V, Vulpiani M, Torrisi M, Ferretti A, Pavan A, Vetrano M. Experimental studies on the biological effects of extracorporeal shock wave therapy on tendon models. A review of the literature. Muscles Ligaments Tendons J 2019. [DOI: 10.32098/mltj.03.2014.15] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
17
|
Erroi D, Sigona M, Suarez T, Trischitta D, Pavan A, Vulpiani M, Vetrano M. Conservative treatment for Insertional Achilles Tendinopathy: platelet-rich plasma and focused shock waves. A retrospective study. Muscles Ligaments Tendons J 2019. [DOI: 10.32098/mltj.01.2017.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
18
|
Bonanno L, Zulato E, Attili I, Pavan A, Del Bianco P, Nardo G, Verza M, Pasqualini L, Pasello G, Zago G, Frega S, Fassan M, Calabrese F, Amadori A, Guarneri V, Conte P, Indraccolo S. Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Bonanno L, Pavan A, Dieci MV, Di Liso E, Schiavon M, Comacchio G, Attili I, Pasello G, Calabrese F, Rea F, Favaretto A, Rugge M, Guarneri V, Fassan M, Conte PF. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. Eur J Cancer 2018; 101:191-200. [PMID: 30077124 DOI: 10.1016/j.ejca.2018.06.023] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Revised: 06/18/2018] [Accepted: 06/20/2018] [Indexed: 10/28/2022]
Abstract
INTRODUCTION The prognosis of small-cell lung cancer (SCLC) is dismal and new effective therapies are needed. Immunotherapy looks promising, but no molecular predictive markers are currently available, and data on immune microenvironment are very limited. METHODS We retrospectively analysed 104 SCLC cases. Immunohistochemistry evaluation of PD-L1 was performed both on tumour cells (TCs) and on tumour-infiltrating immune cells (TIICs) by using anti-PD-L1 22C3 antibody (DAKO) and categorised by using 1% as cut-off point. Tumour-infiltrating lymphocytes (TILs) were characterised by using anti-CD8 and anti-FOXP3 antibodies. Semi-quantitative score was used and categorised as positive versus negative/low. The relation of molecular markers with prognosis and with clinical variables was evaluated. RESULTS The analysis included 66 stage I-III patients (48 surgically resected, 18 treated with radical-intent chemoradiotherapy) and 38 metastatic cases. In the overall study population, PD-L1 was expressed on TCs and TIICs in 25% and 40% of cases, respectively. The proportion of PD-L1-positive cases was significantly higher in stage I-III versus metastatic patients (32% versus 13%, p: 0.034 for TCs; 51.5% versus 21% for TIICs, p: 0.002). CD8- and FOXP3-positive TILs were present in 59% and 72% of samples, respectively. The presence of FOXP3-TILs was associated with improved prognosis among non-metastatic patients, with a hazard ratio for survival of 0.32 (95% confidence interval [CI]: 0.16-0.7, p: 0.006) for univariate analysis, and 0.37 (95% CI: 0.17-0.81, p: 0.013) for multivariate analysis. CONCLUSIONS Immune contexture of SCLC may differ according to stage. The presence of FOXP3-positive TILs is a potential prognostic marker for stage I-III SCLCs and warrants further investigation.
Collapse
|
20
|
Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli G, Schiavon M, Pezzuto F, Pavan A, Vuljan S, Del Bianco P, Conte P, Rea F, Calabrese F. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor heterogeneity over time. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy086] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|
21
|
Pavan A, Fassan M, Dieci M, Attili I, Pasello G, Calabrese F, Rea F, Rugge M, Conte P, Bonanno L. 78O Immune microenvironment of small cell lung cancer (SCLC): Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumor infiltrating lymphocytes. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30353-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
22
|
Bonanno L, Attili I, Zulato E, Nardo G, Verza M, Pavan A, Del Bianco P, Pasello G, Zago G, Polo V, Frega S, Milite N, Carlucci M, Calabrese F, De Salvo G, Conte P, Indraccolo S. P3.02-006 Monitoring Genetic Alterations in Plasma during Anti-Cancer Treatment in Advanced NSCLC (MAGIC1-Validation Cohort: Preliminary Results). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
23
|
Di Liso E, Pavan A, Schiavon M, Gregori D, Comacchio G, Attili I, Mantiero M, Pasello G, Zago G, Polo V, Frega S, Milite N, Rea F, Conte P, Bonanno L. Surgery in multimodal management in non-metastatic small cell lung cancer: a retrospective monocentric series. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Frega S, Macerelli M, Del Conte A, Bonanno L, Bartoletti M, Polo V, Zago G, Follador A, Attili I, Pavan A, Urso L, Basso S, Fasola G, Conte P, Pasello G. Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Zago G, Lunardi F, Calabrese F, Vuljan S, Urso L, Frega S, Pavan A, Polo V, Bonanno L, Attili I, Rea F, Conte P, Pasello G. Malignant pleural mesothelioma immune microenvironment and checkpoint expression before and after systemic cytotoxic treatment. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx389.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|